Aja Health and Wellness Inc. Announces Launch of Nasal Product for Migraine Headache Relief and Provides Update on Delay in Filing Financial Statements

Core Viewpoint - Aja Health and Wellness Inc. is launching a nasal spray product for migraine relief, targeting a significant market of migraine sufferers in the United States and globally [2][4]. Product Launch - Aja Therapeutics Inc. has completed initial testing of the nasal spray and plans to release it for retail sale in the United States on May 28, 2025, available for purchase at www.easemyheadache.com [3]. - The nasal spray utilizes a proprietary flavonoid extract that aims to provide fast relief from migraine pain without side effects or long-term damage [4]. Market Opportunity - There are approximately 32 million migraine sufferers in the United States seeking alternatives to traditional migraine treatments, with an additional 16 million in Canada and the United Kingdom, indicating a substantial global market opportunity for the product [4]. Financial Reporting Update - Aja is nearing the completion of its annual audited financial statements for the year ending December 31, 2024, after a delay caused by the auditors' need for guidance on a reverse takeover transaction [5][6]. - The company expects to engage a valuator by June 2, 2025, to complete the necessary valuation for the financial statements, with an anticipated filing date for the required annual filings by July 31, 2025 [6]. Interim Financial Statements - Due to the delay in annual filings, Aja anticipates being unable to file its unaudited interim financial statements for the three months ended March 31, 2025, by the May 30, 2025 deadline, but plans to file them concurrently with the annual filings [9].